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CLINICAL AND EPIDEMIOLOGICAL STUDY OF 
BRONCHIAL ASTHMA IN CHILDREN & ASSESSMENT 
OF SEVERITY OF ASTHMA AND ITS CORRELATION 
WITH SERUM  IgE  LEVELS
ABSTRACT
BACKGROUND:
        Bronchial asthma is a common chronic disease which is increasing 
in prevalence among children worldwide. IgE plays a major role in the 
pathogenesis of asthma. This study was done to assess the correlation of 
serum IgE levels with various grades of asthma and also the association 
of various epidemiological factors to the severity of asthma.
METHODOLOGY:
        This is a case study performed over 75 asthmatic children who were 
attending outpatient as well those admitted in our pediatric ward from 
October 2011 to September 2012. The study also included 75 healthy 
controls. Detailed history including passive smoking, duration of breast 
feeding, family history and age of onset was taken. Severity of Asthma 
was assessed clinically and by Spirometry. Serum IgE levels were 
estimated using Elisa kit.
RESULTS:
        In our study there was significant association of serum IgE levels 
with the severity of asthma ( p < 0.005 ). IgE levels did not differ 
significantly in different age groups and both sexes. Significant 
association was present between the severity of asthma and family 
history, passive smoking, atopic eczema, duration of breast feeding & 
duration of the disease ( p < 0.005 ).
CONCLUSION:
        IgE plays a definite role in the prevalence and severity of asthma. 
Estimation of serum IgE levels and assessment of severity helps in 
effective management of asthmatic children. Anti – IgE therapy will be 
beneficial in moderate to severe asthmatics. Promotion of breast feeding, 
avoidance of exposure to passive smoking and other triggering factors 
could reduce the severity of asthma thereby decreasing the morbidity and 
mortality.
KEYWORDS:
         Bronchial asthma, IgE, Breast feeding, passive smoking and atopic 
eczema.
INTRODUCTION
Allergic respiratory diseases, particularly Bronchial asthma is 
increasing in prevalence among children globally.  Asthma is the most 
common chronic disease worldwide.  It affects persons of all ages.
          Genetic predisposition is one of the reasons for increased 
prevalence in children and other factors like air pollution, urbanization
and environmental tobacco smoke also contribute more significantly.
Asthma poses a significant burden not only in terms of health care 
costs but also of lost productivity and reduced participation in family life. 
When uncontrolled, Asthma place severe limits on daily life and is 
sometimes fatal.
DEFINITION OF BRONCHIAL ASTHMA:
Asthma is defined as a reversible chronic inflammatory condition 
of lung airways resulting in episodic air flow obstruction.It is 
characterized by recurrent episodes of wheezing, chest tightness and 
coughing alternating with periods of relatively normal breathing.
EPIDEMIOLOGY AND BURDEN OF ASTHMA:
The word asthma is derived from Greek verb “aazein” meaning to 
breathe hard.  Asthma affects about 300 million people in the world.1,2
Various epidemiological studies carried out in different countries 
indicate the prevalence of respiratory allergic diseases as 14-30 percent.  
In children and adult the global prevalence of asthma ranges from 3.5-
20% of the population in any country.3
The increase in prevalence over the last 25 years possibly reflects 
the changes in our environment (or) life style, greater awareness of this 
condition and improvements in diagnostic practices.
World wide, asthma cases are increasing at a rate of 50 percent 
every decade.  The prevalence of asthma is the highest in developed 
countries such as United States, United Kingdom, Australia, Newzealand
and North West Europe and is increasing in developing countries like 
India.
The prevalence of asthma is higher in urban areas compared to 
rural areas.  Most of the asthmatics develop symptoms before the age of 
ten. Among young children the prevalence of asthma is slightly higher in 
boys than in girls, however after puberty it is more common in female.
It has been estimated that our country has approximately 15-20 
million asthmatics and it accounts for one third of World’s asthma 
patients.  Between 5-11 years of age 10-15% is affected.4
In rural children in Delhi, Parental smoking, paracetamol intake, 
exposure to traffic pollution, exposure to pets were significantly 
associated with current wheezing whereas in children aged 4-15 years in 
Chandigarh, a prevalence of 7 percent was observed. 5
The World Health Organization has estimated that 15 million 
Disability Adjusted Life Years (DALYs)6 are lost annually due to asthma, 
representing 1% of the total global disease burden.Absence from school 
and days lost from work are reported as substantial social and economic 
consequence of asthma.
PATHOGENESIS AND PATHOPHYSIOLOGY OF 
ASTHMA:
Airway inflammation is a major factor implicated in the 
pathogenesis and pathophysiology of asthma
Inflammation
Airway hyperresponsiveness Airway obstruction
Clinical symptoms
Air flow limitation in asthma is recurrent and it is caused by 
variety of changes in airway.  The four main pathological changes in 
asthma are
1. Bronchoconstriction
2. Airway edema
3. Airway Hyperresponsiveness
4. Airway remodeling
1.BRONCHOCONSTRICTION:
The predominant event in asthma is narrowing of air ways, which 
result in interference with airflow.  In acute exacerbations of asthma, 
bronchial smooth muscle contraction occurs resulting in airway
narrowing in response to a variety of stimuli including allergens (or) 
irritants.
Allergen induced acute bronchoconstriction results from IgE 
dependent release of mediators from mast cells that include histamine, 
tryptase, leukotrienes and prostaglandins that directly constrict air way 
smooth muscles.7
In addition other stimuli including exercise, cold and irritants can 
cause acute air flow obstruction. Stress may also precipitate asthma 
exacerbation by enhanced generation of proinflammatory cytokines.
2. AIRWAY  EDEMA:
As the inflammation becomes more progressive and disease 
becomes persistent other factors further limit airflow. These includes
Edema
Inflammation
Excess secretion of mucus
Formation of thick mucus plugs
Hypertrophy and hyperplasia of airway smooth muscle
3. AIRWAY HYPERRESPONSIVENESS:
It is an exaggerated bronchoconstrictor response to a wide variety 
of stimuli. Inflammation is a major factor determining the degree of 
airway responsiveness. Other factors include structural changes and 
dysfunctional neuro regulation.
4. AIRWAY REMODELING:
Airway remodeling8 involves activation of many structural cells 
which in turn cause permanent changes in the airway that increase airflow 
obstruction and hyperresponsiveness.
These structural changes include
Thickening of Basement membrane
Sub epithelial fibrosis
Airway smooth muscle hypertrophy and hyperplasia
Proliferation and dilatation of blood vessels 
Mucus gland hyperplasia and hypersecretion.
Therefore the key events involved in persistent nature of the disease and
decreased responsiveness to therapy are the process of repair and its 
regulation. The resulting airway obstruction leads to ventilation perfusion 
mismatch which in turn causes hypoxemia, hyperventilation or 
hypoventilation.
Figure 1            PATHOGENESIS OF BRONCHIAL ASTHMA
           
PATHOPHYSIOLOGIC MECHANISMS OF AIRWAY
INFLAMMATION:
Many types of cells and multiple mediators are involved in airway 
inflammation.
INFLAMMATORY CELLS:
1. LYMPHOCYTES:
There are two subsets of T-lymphocytes, Th1 & Th2.  In asthma 
Th2 plays a major role in generating the cytokines like IL4, IL5 and
IL 13.9  These cytokines are responsible for over production of IgE, 
Eosinophils and development of airway hyperresponsiveness.
2. MAST CELLS:
Mast cells present in bronchial smooth muscle cells have IgE 
receptors.  Allergens bind to IgE receptors and activate mast cells 
releasing bronchoconstricting mediators like Histamine, Leukotrienes and 
Prostaglandins.10,11,12
3. EOSINOPHILS:
Almost all of the asthmatics have increased number of eosinophils
in their airways.  These cells contain inflammatory enzymes, generates 
Leukotrienes and wide variety of proinflammatory cytokines responsible 
for airway hyperresponsiveness.13,14,15
4. MACROPHAGES:
There are numerous macrophages in airways which have low 
affinity IgE receptions that may also play a role in inflammatory 
response.
5. EPITHELIAL CELLS:
Epithelial cells lining the airway epithelium produce more 
inflammatory mediators when exposed to mediators produced by other 
inflammatory cells and also by viral infections.  This results in epithelial 
damage worsening the airway obstruction.16
INFLAMMATORY MEDIATORS 
1. CHEMOKINES:
Chemokines play a role in recruitment of inflammatory cells and 
are responsible for maintaining the allergic inflammatory response.17
They are generated by T cells, mast cells, smooth muscle cells, 
fibroblasts, epithelial cells and endothelial cells. Of the chemokines 
eotaxin is selective in recruiting the eotaxin.  TH2 cells are recruited by 
activation regulated and macrophage derived chemokines.
2. CYTOKINES:
           Cytokines are mediators involved in chronic inflammation of 
airways even in mildest form of asthma. They are produced by T
lymphocytes, eosinophils, epithelial cells, endothelial cells and 
fibroblasts. Cytokine like IL3 is a mast cell growth factor and stimulates 
proliferation of eosinophils from bone marrow stem cells. GM –CSF, IL3 
and IL5 promote maturation and differentiation of eosinophils. 
Interferon-γ       and IL4 regulate IgE production. They cause selective 
recruitment and accumulation of eosinophils in the airways by induction 
of various adhesion molecules. Cytokines act upon inducible nitric oxide 
synthetase and increase nitric oxide production.
3. CYSTEINYL – LEUKOTRIENES:
These are potent bronchoconstrictors derived mainly from mast 
cells whose inhibition has been specifically associated with an 
improvement in lung function and asthma symptoms.18,19
4.NITRIC OXIDE:
           It is a potent vasodilator produced by the action of NO synthase in 
airway epithelial cells.20,21 NO plays a key role, both in the physiological 
regulation of the airways and the pathophysiology of asthma. Three forms 
of NO synthetase act upon aminoacid L - arginine to produce NO 
endogenously. NO produced by neuronal NOS ( nNOS ) results in 
bronchodilatation. NO produced by the endothelial cell NOS ( ecNOS ) 
and inducible  NOS  ( iNOS) cause bronchoconstriction by 
vasodilatation, plasma exudation, mucus secretion and indirect activation
of TH2 lymphocytes, worsening the asthmatic inflammatory response.22
Inducible NOS is inhibited by corticosteroid therapy. Selective inhibition 
of this enzyme is likely to prove beneficial in the treatment of asthma. 
Measurements of fractional exhaled NO (FeNO) is useful in monitoring 
response to asthma treatment.23
5.IgE:
IgE is the antibody produced by the plasma cells of lymph nodes.  
It plays a major role in activation of mast cells and basophils and 
releasing inflammatory mediators in response to allergen.
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GENETICS OF ASTHMA
           Asthma is a disease which has strong genetic predisposition.
Maimonides first recognised the familial nature of asthma in the 12th
century. Because Asthma runs in families it is likely to be, at least in part 
linked to genetic factors. Identification of potential candidate genes by 
the whole genome screen will lead to new and better ways of diagnosis of 
asthma; identify a particular clinical course and response to therapy. The 
scope of drug discovery related to products of candidate genes is also 
widening.
ROLE OF GENETICS IN THE DEVELOPMENT OF ASTHMA:
           More than 100 genetic loci24 have been linked to asthma. Although 
the genetic linkages to asthma have sometimes differed between cohorts, 
asthma has been consistently linked with loci containing proallergic, pro 
inflammatory genes. Genes on chromosomes, 5, 6,11,12,14 seem to be 
the key players in controlling the inflammatory process in asthma and 
atopy.25  Five important genes linked to asthma are PHF11, SPINK5, 
ADAM33 and GRPA. In addition to these, other genes like IL 13 that 
alters the production of mucus, FC εR1- that alter certain innate immune 
receptors and triggering factors on mast cells have also been identified.
ROLE OF GENETICS IN PREVENTION AND MANAGEMENT 
OF ASTHMA:
           Identification of genes implicated in asthma may lead to 
classification of asthma in a better way.Recognition of infants and 
children who are genetically predisposed to asthma would possibly be the 
initial step in strategies for prevention by environmental or other 
manipulations in the first year of life.
EARLY CHILDHOOD RISK FACTORS FOR PERSISTENT 
ASTHMA:
1. Parental Asthma
2. Allergy
Atopic dermatitis (eczema)
Allergic rhinitis
Food allergy
Inhalant allergen sensitization
3. Severe lower respiratory tract infection
Pneumonia
Bronchiolitis requiring hospitalisation
4. Wheezing apart from colds
5. Male gender
6. Low birth weight
7. Environmental tobacco smoke
8. Possible use of acetaminophen (paracetamol)
9. Exposure to chlorinated swimming pools
10. Reduced lung function at birth.26,27
SYMPTOMS OF ASTHMA
Recurrent isolated cough
Recurrent Wheeze, Recurrent breathlessness
Night time cough
Tightness of Chest
Cough or Wheeze induced by exercise.
The symptoms of asthma usually occur during the night time. This 
may be attributed to the hormonal changes that take place during 
later part of the night or early morning. The Serum cortisol and 
epinephrine levels reach nadir in early morning causing increased 
airway resistance and nocturnal symptoms.
EARLY WARNING SIGNS OF ASTHMA:
Increased breathing through mouth during sleep
Increased cough at night
Feeling restlessness during sleep
Increased tiredness during activities
Worsening of symptoms like cough, wheeze or running nose 
during exercise.
TYPES OF CHILDHOOD ASTHMA
          There are two main types of childhood asthma.
1. Recurrent Wheezing
2. Chronic asthma
RECURRENT WHEEZING:
           Recurrent wheeze occur in children less than 3 years. This may be 
due to some viral infections of the respiratory tract that occur during 
childhood and also because of decreased lung function in newborn 
period. As lung function improves with age wheeze will not recur.
CHRONIC ASTHMA:
           This type of asthma is associated with allergy that persists into 
later childhood and often adulthood.
NON ATOPIC WHEEZE:
          If Wheezing recur, after 3yrs of age it is called persistent wheeze. 
The most important cause for this wheeze is respiratory infections caused 
by viruses like RSV. These Viral infections can cause increased tone of 
smooth muscles in the respiratory tract which can improve with age.
ATOPIC WHEEZE:
           This type of Wheeze occurs in children with atopy. It is of two 
types namely early atopic Wheeze and late atopic Wheeze. 
These children are susceptible to various allergens leading to 
hypersensitivity of their airways and obstruction. Children with repeated 
exposures to triggering factors easily develop asthma in their adulthood.
Moral Gil  et al28 revealed that non atopic or transient wheeze was 
classified as non-allergic type of asthma. 
But Taussig et al29 in his study mentioned that asthma in children which 
is caused by many factors cannot be grouped into any type.
O’ Connell et al30 reported that, wheezing in children of 8 years of age 
with hypersensitivity and smoking history in the family was 28 times 
more than normal children. Recently, environmental factors have found 
to play an important role in allergic asthma when compared to genetic 
factors.
TRIGGERS OF ASTHMA
Asthma symptoms are triggered by many factors such as allergies 
and activities.
ENVIRONMENTAL FACTORS:
1. ALLERGENS:
Indoor:   Domestic mites, furred animals, dogs, cats, mice) 
cockroach allergens, fungi, moulds, yeast.31, 32
          Outdoor: Pollens, fungi, moulds, yeast
2. Infections (especially viral)
3. Occupational sensitizers
4. Tobacco smoke
5. Outdoor / Indoor air pollution
6. Food allergy
HOST FACTORS: 
i) Genetic 
(1)Genes predisposing to atopy 
(2)Genes predisposing to airway hyperresponsiveness
ii) Obesity
iii) Sex
Around Eighty percent of people with asthma have allergies to 
airborne substances, such as tree, grass, weed pollens mold, animal 
dander, dust mites etc. It has been found that children who had high 
levels of cockroach droppings in their homes were four times likely to 
have childhood asthma than children who had low levels of these 
droppings at home.33, 34
FOOD AND FOOD ADDITIVES THAT TRIGGER ASTHMA:
Allergies to food can lead to mild to severe life threatening 
reactions.  Some of the most common foods associated with allergic 
manifestations are 
Eggs
Peanuts
Fish, Shell fish
Cow’s milk
Wheat
Salads & fresh fruits, 
Food preservatives can also trigger asthma in those children who 
are sensitive.  These include Sodium bisulfite, Potassium bisulfite, 
Sodium meta bisulfite, potassium meta bisulfite and sodium sulfite.
ASTHMA & COLD AIR
Changes in Air temperature provoke symptoms of asthma. Going 
from a warm room into cold air outside triggers allergic symptoms.
ASTHMA AND DRUGS:
Certain drugs also trigger asthma symptoms.  These include 
aspirin, beta blockers NSAIDS such as Ibuprofen.
OTHER TRIGGERS:
Paint fumes
House hold chemicals such as those found in air fresheners
Perfumed cosmetics
Strongly scented flowers
Exercise and Emotions.
IGURE 3              TRIGGERS OF ASTHMA
    
OBESITY:
Obese individuals are more at risk of developing asthma.  How 
obesity promotes the development of asthma is unclear. Obese patients 
have a reduced expiratory reserve volume which may alter airway smooth 
muscle plasticity and airway function.  Furthermore release of 
proinflammatory cytokines and mediators such as Interleukin 6, TNF-α, 
eotaxin and leptin by adipocytes combined with a lower level of anti 
inflammatory adiopkines in obese subjects can favor a systemic 
inflammatory state.35-37
IgE IN BRONCHIAL ASTHMA:
IgE is a class of antibody (or) immunoglobulin found only in 
mammals.  It was discovered in 1966 by Japanese scientist Teruko and 
Dikimishiga – Ishizaka.  IgE is produced by plasma cells and 
B lymphocytes in airway, regional lymph nodes and gastrointestinal tract.  
It comprises only 0.001% of circulating immunoglobulin. Normal IgE 
levels ranges from 0 -230 IU/ml in male children and 0 – 170 IU/ml in 
female children.38
IgE plays an essential role in type I hypersensitive reactions which 
manifest various allergic diseases like asthma, allergic rhinitis, food 
allergy, urticaria and atopic dermatitis.  It mediates the allergic response 
by binding to Fc receptors, found on surface of mast cells and 
basophils.39-42
Binding of IgE to mast cells initiate an allergic cascade.
FIGURE 4                  STRUCTURE OF IgE
STEPS INVOLVED IN ALLERGIC CASCADE:
Sensitization to an allergen
Early phase reaction
Last phase reaction.
1. SENSITIZATION TO AN ALLERGEN:
In susceptible individuals, the first step in developing an allergic 
reaction is repeated exposures to a particular antigen.  Some allergens 
cause mild reactions and some can trigger strong allergic reaction. 
           Allergens induce the T cells which then activate B cells. Activated 
B cells get transformed into plasma cells.  These plasma cells are capable 
of producing and releasing more antibodies.
EARLY PHASE REACTION:
This phase begins with binding of IgE to mast cells, which occurs 
within half an hour after initial exposure. IgE mediates allergic response 
by binding to specialized receptors called Fc receptors on the surface of 
mast cells and basophils.  Fc receptors are of two types, Type I and    
Type II.
Type I Fc receptors are high affinity IgE receptors, found in 
basophils and mast cells.  Type II receptors also known as CD23 are low 
affinity IgE receptors found in B cells,macrophages , eosinophils and 
platelets.When a substantial mass of IgE binds to mast cells, it release 
histamine and other inflammatory mediators and initiates the allergic 
reaction.43
LATE PHASE REACTION:
It usually begins at the same time as early phase reaction but the 
symptoms manifest some 3 to 10 hours later.  This phase involves 
immune cells such as eosinophils.  During this phase the symptoms 
become more severe than those seen during the early phase and it also 
lasts for 24 hours (or) more before subsiding.43
CONSEQUENCES OF CHRONIC ALLERGY AND REACTION IN 
ASTHIMA
Repeated exposures to an allergen and subsequent allergic reaction 
leads to airway hyperresponsiveness and airway remodeling. These 
changes can cause permanent damage to the airway.  Long term 
controller medications that significantly reduce airway inflammation and 
maintain maximum lung function can lessen the risk of permanent 
damage.
DIAGNOSIS OF ASTHMA
PULMONARY FUNCTIONS TESTS
Pulmonary function test is one of the basic tool in evaluating a 
patient’s respiratory status.  In day to day practice the common lung
function tests used to diagnose asthma are spirometry and peak expiratory 
flowmetry.  These tests are usually preformed in children above 5-6 years 
of age.44
SPIROMETRY:
Spirometers are instruments used for spirometry and spirogram is 
the tracing generated by the spirometer. Spirometry provides an objective 
assessment of air flow obstruction and is useful in the staging of asthma 
according to severity.  It is used to measure the maximal expiratory effort 
following maximal inhalation.45
The four indices that are mainly used to interpret spirometry are 
forced vital capacity (FVC), forced expiratory volume (FEV1), forced 
expiratory ratio (FEV1/FVC) and forced expiratory flow (FEF). In 
Asthma the forced expiratory volume in 1 second (FEV1) is usually 
decreased, the forced vital capacity is usually normal and the ratio 
FEV1/FVC is decreased. 
           The success of spirometry depends mainly in producing an 
acceptable and reproducible FVC curve.  Only with adequate training and 
encouragement, children above 5-6 years can produce an acceptable FVC 
curve.
PEAK EXPIRATORY FLOW METRY:
Peak flow meter is a portable, handy device, used to measure peak 
expiratory flow rate.  It can be easily and accurately performed by 
children more than 5 years.  It is useful in the diagnosis and monitoring of 
asthma patients regularly .Children with Asthma can use this device at 
home to record and monitor their peak flow rate.46,47,49
Peak expiratory flow rate is the maximum flow rate generated 
during a forceful exhalation after maximal inspiration. It correlates with 
FEV1 in spirometry.
The PEFR reading is correlated with the predicted values from 
standard normogram based on height of the child. The formula used to 
calculate PEFR, 
                      
5  PEAK FLOW METER
6 CHILD PERFORMING PEAK  FLOW METRY
PEFR    =   [(Ht in cms -100) x 5] +100
PEFR values <80% of predicted values are considered abnormal. 
           Further confirmation can be done by a bronchodilator reversibility 
test.>20% improvement in recording after giving a bronchodilator 
confirms reversible bronchospasm.48-50
A diurnal variation in PEFR of >20% is also an indicator of 
asthma.
EXERCISE TEST:
PEFR is recorded following a vigorous exercise for 5-6 minutes.  A 
fall in PEFR by at least 15% at the end of the test is useful in diagnosing 
exercise induced asthma.
METHACHOLINE CHALLENGE TEST:
          The presence of airway hyperresponsiveness can be determined by 
Methacholine bronchial provocation challenge. In this procedure patients 
are allowed to inhale increasing concentrations of Methacholine. 
Methacholine is a cholinergic agonist which acts by stimulating the 
muscarinic receptors on smooth muscle cells in the airway to cause 
constriction.
           Patients with asthma are more sensitive to methacholine than 
normal individuals. The smooth muscles in their airway constricts at 
lower concentrations of this medication. The results of this test are 
typically expressed as a provocative concentration of methacholine that 
causes 20% of decline in FEV1 (denoted as PC 20). A methacholine 
PC20 of less than 8mg/dl has sensitivity of 100% for asthma. A PC20 
between 2 and 8 mg/dl is considered mild asthma. It is a more clinically 
useful tool to exclude the diagnosis of asthma.51-53
EXHALED NITRIC OXIDE:
           Exhaled Nitric Oxide is an inflammatory by product which is 
elevated in asthmatics. In 1991, the nitric oxide was first identified in 
breath samples that are exhaled. In 1993, exhaled Nitric Oxide (eNO) was 
reported in asthmatics by researchers from Sweden. It can be elevated in 
atopy alone and is not always an indicator of asthma.
However exhaled nitric oxide (FeNO) is used as a diagnostic tool for 
asthma in corticosteroid sensitive patients and it is rapidly reduced by 
inhaled corticosteroids. Patients with FeNO guided inhaled corticosteroid 
therapy have good level of asthma control achieved at lower doses of 
corticosteroid.54,55
           Hence FeNO may be useful in providing an indication of 
corticosteroid sensitivity, monitoring asthma control and guiding therapy 
in corticosteroid responsive cases.
SKIN PRICK TEST (ALLERGY TESTING):
           Skin Prick Test is quiet reliable, rapid and cost effective that is 
useful in determining the triggers of asthma. In this test the IgE 
medicated responses are identified by injecting particular antigens into 
the skin. These antigens trigger mast cells in children with allergies. 
Activated mast cells release mediators like histamine which can induce 
itching, swelling and redness. A wheal of 3mm (or) more in diameter is 
considered as positive. These tests will be helpful in effective 
management of asthmatic children by avoidance of specific allergies.56
GLOBAL INITIATIVE FOR ASTHMA (GINA) GUIDELINES
FOR ASSESSING SEVERITY:
The global initiative for Asthma was formed in 1993.  Its goals and 
objectives were described in a 1995 NHLBI / WHO workshop report, 
global strategy for Asthma, Management and prevention.
  
              In 2002 guidelines were phrased based on severity of Asthma.
Patients were graded into intermittent, mild, moderate and severe grades 
of asthma based on these guidelines.57,58
Table 1                 Grading of Asthma
SEVERITY INTERMITTENT PERSISTENT
MILD MODERATE SEVERE
DAY 
SYMPTOMS
< 1 per week ≥ 1 per 
week
Daily
Affects daily 
activities
Daily
Limits 
daily 
activities
NIGHT 
SYMPTOMS
≤ 2 per month ≥ 2 per 
month
>1 per week Frequent
PEF ≥ 80% predicted ≥ 80% 
predict
ed
>60 <79% 
predicted
<60% 
predicted
PEF 
VARIABILITY
≤ 20% 20 -
30%
>30% >30%
FEV1 ≥ 80% ≥ 80% 60 -79% <60%
MANAGEMENT OF ASTHMA
GOALS OF ASTHMA THERAPY:
 To prevent chronic and troublesome symptoms i.e., cough, 
breathlessness in the night, early morning (or) post exertion.
 To minimize the frequent need of quick reliever medications.
 To maintain near “normal” pulmonary function.
 To maintain normal activity levels including physical 
activity and school attendance.
 To prevent recurrent exacerbations and minimize the need 
for emergency visits and hospitalization.
 To provide optimal therapy with minimal or no adverse 
effects.
 To meet patients and families expectations of and 
satisfactions with asthma care.
The choice of initial therapy is based on assessment of asthma severity, 
and for patients who are already using controller therapy, modification of 
treatment is based on assessment of asthma control and responsiveness to 
therapy.
           Persistent asthma is most effectively controlled with daily anti 
inflammatory therapy. Under diagnosis and inappropriate therapy are 
major contributors to asthma morbidity and mortality.
LONG TERM CONTROLLER MEDICATIONS:
           Long-term medications for control are used to achieve and 
maintain control of persistent asthma.
These include 
1. Corticosteroids
2. Long acting inhaled –β agonist
3. Leukotriene modifiers
4. Non-steroidal Anti-inflammatory agents
5. Methylxanthines
INHALED CORTICOSTEROIDS:
           Inhaled corticosteroid therapy has been shown to improve lung 
function, as well as to reduce symptoms, AHR and use of rescue 
medications.It has been found to reduce emergency care visits and 
hospitalizations by about 50% .The NIH guidelines recommend daily ICS 
therapy as the treatment of choice for all patients with persistent asthma. 
ICS therapy may lower the risk of death due to asthma. These are 
available as metered-dose inhalers (MDIs), dry powder inhalers (DPIs) or 
as suspension for nebulisation.
The currently used ICS in asthma are Budesonide, fluticatosone 
propionate and beclomethasone.59-63
SYSTEMIC CORTICOSTEROIDS:
           Oral corticosteroids are used primarily to treat asthma 
exacerbations and rarely in patients with severe disease who remain 
symptomatic despite optimal use of other asthma medications. 
Predinisolone and methyl predinisolone are steroids that are used orally.
LONG-ACTING INHALED β-AGONISTS:
          These are long acting bronchodilators used concomitantly with 
anti-inflammatory drugs to achieve long term control, especially 
nocturnal symptoms. They are not used as rescue medications for acute 
asthma symptoms or exacerbations, nor as monotherapy for persistent 
asthma. LABs major role is, as an add on agent in patients whose asthma 
is sub optimally controlled with ICS therapy alone. Several studies have 
found that addition of an LAB to ICS therapy to be superior to doubling 
the dose of ICS, especially on day and night symptoms.59,63,65
LEUKOTRIENE MODIFIERS:
           Leukotrienes are potent pro-inflammatory mediators that can 
induce bronchospasm, mucus secretion and airway edema. There are two 
types of Leukotriene modifiers.
1. Leukotriene synthesis inhibitors
2. Leukotriene receptor antagonists (LTRAs)
           Zileuton, the only leukotriene synthesis inhibitor is not approved 
for use in children <12 years of age. LTRAs have bronchodilator and 
targeted anti-inflammatory properties and reduce exercise, aspirin and 
allergen induced bronchoconstriction. They are recommended as 
alternative treatment for mild persistent asthma and as add-on medication 
with ICS for moderate persistent asthma.
Two LTRAs that are FDA approved for use in children are montelukast 
and Zafirlukast. Montelukast is used for children > 1 year of age and 
Zafirlukast is used in children >5 years of age.64
NON STEROIDAL ANTI INFLAMMATORY AGENTS:
           Cromolyn and nedocromil are NSAIDS that may be used as initial 
choice for long term control. It is also used as preventive therapy prior to 
exercise (or) unavoidable exposure to known allergens. They can be used 
in place of SABAs especially in children who develop unwanted effects 
with β-agonist therapy.
METHYLXANTHINES:
           Sustained release theophylline is a mild to moderate
bronchodilator used as an adjuvant to inhaled corticosteroids for 
prevention of nocturnal symptoms. It may also have anti inflammatory 
effects. When used long term, theophylline can reduce asthma symptoms 
and the need for rescue SABA use.66
QUICK RELIEF MEDICATIONS:
           Quick Relief medications are used to treat acute symptoms and 
exacerbations.
It includes
1. Short acting inhaled β-agonists.
2. Anticholinergics
3. Systemic corticosteroids
SHORT ACTING INHALED β-AGONISTS
            SABAs like Albuterol, Levalbuterol, terburtaline, pirbuterol are 
the drugs of choice for acute asthma symptoms and preventing exercise 
induced bronchospasm. β-Agonists cause broncodilation by inducing 
airway smooth muscle relaxation, reducing vascular permeability and 
airway edema and improving mucociliary clearance.
ANTI CHOLINERGIC AGENTS:
         Inhaled Ipratropium is used primarily in the treatment of acute 
severe asthma. It is proving to be of immense value in infant wheezers
and severe persistent asthmatics. But they are much less potent that β-
Agonists.
SYSTEMIC CORTICOSTEROIDS:
          Used in moderate to severe exacerbations to speed recovery and 
prevent recurrence of exacerbations.
ANTI –IgE THERAPY IN ASTHMA:
As IgE plays a major role in type I hypersensitivity reactions, it has 
been found out that any means of reducing circulating levels of IgE 
would be helpful in the treatment of allergic diseases especially asthma.
IgE exerts its effect by binding to high affinity Fc epsilon receptors 
on mast cells, eosinophils and basophils.  These receptors are also found 
in Dentritic cells particularly type II dentritic cells which support Th2 
responses.
Omalizumab is a newly discovered recombinant humanized 
monoclonal antibody.  It acts by preventing the binding of IgE to high 
affinity receptors and initiation of allergic immune response. Treatment
with this drug has resulted in noticeable reduction in free IgE levels and 
also down regulation of IgE receptors on dentritic cells and basophils.
              Omalizumab has showed promising results in the treatment of 
moderate to severe allergic asthma by reducing exacerbations and need 
for corticosteroid. In a double blind, parallel multicenter study, it was 
shown that Omalizumab was successful in the treatment of difficult to 
treat asthmatics as add on therapy.67-69
Several studies have also revealed that this drug has altered the 
cytokine levels as well as number of Fc epsilon receptors (or) IL4 cells 
and also reduced airway eosinophilia.
MEPOLIZUMAB:
           It is a newly introduced anti-interleukin 5 antibody which has 
shown to improve asthma control, reduce predinisolone dose and lower 
sputum and blood eosinophil events in adults with prednisone dependent 
asthma who also had sputum eosinophils.70
ROLE OF BREAST FEEDING IN ASTHMA:
It was shown that prolonged breast feeding could reduce the risk of 
allergic and respiratory diseases.  There are numerous studies which have 
shown that exclusive breast feeding for a period of at least 3 months have 
protective effect in the development of asthma and other allergic diseases.
In a cross sectional study conducted in 1500 infants from well baby 
clinic & pediatric clinics in the state of Qatar from October 2006 to 
September 2007, more than half of the infants (59.3%) were exclusively 
breastfed, 28.3% were partially breastfed and 12.4% were artificially fed.  
The incidence of Asthma (15.6%), wheezing (12.7%), Allergic rhinitis
(22.6%) and eczema (19.4%) were found to be lower in exclusively 
breastfed children.  The risk of allergic diseases were found to be lower 
particularly in children with prolonged breast feeding > 6 months than in 
those children who are breastfed for short term (<6 months).71,72
STRATEGIES FOR AVOIDING COMMON TRIGGERING 
FACTORS:
1. Children should stay away from tobacco smoke. Parents and 
relatives should be advised not to smoke at least indoor.
2. Drugs, foods and additives that are known to precipitate 
symptoms of asthma should be avoided.
3. Bed linens and blankets must be washed weekly in hot water 
and dried in a hot dryer or the sun.
4. Pillows and Mattresses should be encased in air-tight cover.
5. Carpets must be replaced with hard flooring especially in 
sleeping rooms.
6. Pet animals should be removed from the home (or) at least 
from the sleeping area.
7. House should be cleaned thoroughly and frequently.
8. Pesticide spray can be used to avoid cockroaches.
9. Windows and doors should remain closed when pollen and 
mould counts are highest.
10.Any damp area in the home should be cleaned frequently.
AIM OF THE 
STUDY
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AIM OF THE STUDY
1. To assess the severity of Asthma clinically and by peak flow 
metry.
2. To estimate serum IgE levels in Asthmatic children.
3. To compare the serum IgE levels in mild, moderate and severe 
grades of Asthma.
4. To study the association of various epidemiological factors to 
severity of asthma.
NATURE OF STUDY:
           Case Study
PLACE OF STUDY:
          Govt. Mohan Kumaramangalam Medical college hospital, Salem –
636001
PERIOD OF STUDY:
           October 2011 to September 2012
INCLUSION CRITERIA:
Children between 5-12 years of age and both sexes with symptoms 
and signs suggestive of asthma.
EXCLUSION CRITERIA:
1. Asthmatic who had taken bronchodilator with in 24 hrs prior to 
assessment.
2. Chronic respiratory diseases other than asthma
3. Children with history suggestive of worm infestation.
4. Immunocompromised children.
MATERIALS
AND
METHODS
MATERIALS AND METHODS
  The study population included 75 children from those attending 
the outpatient as well as those admitted in the department of pediatrics of 
Government Mohan Kumaramangalam Medical College Hospital, Salem 
with symptoms and sign suggestive of bronchial asthma.
Detailed history was taken regarding patients name, age, sex, 
duration, frequency of symptoms and severity of exacerbations.  All cases 
were provided with a respiratory questionnaire which included questions 
on respiratory symptoms, passive smoking, family history and previous 
medical history. Age and sex matched 75 healthy volunteers were taken 
as control group.
The study was approved by ethical committee and informed 
consent was obtained from all cases and controls.  Peak flow metry was 
carried out in all children, as there was difficulty in obtaining an 
acceptable FVC curve by spirometry. Severity of asthma was assessed by 
clinical history and peak flowmetry. The cases were categorized into 
intermittent, mild, moderate and severe grades of asthma based on global 
initiative for Asthma guidelines 2002.
After taking necessary aseptic precautions, blood samples were 
collected from each patient.  The samples were left undisturbed for about 
half an hour to allow for clot formation.  After complete formation of 
clot, the samples were centrifuged to separate the serum.  The centrifuged 
samples were stored at -20 0C till the analysis was done.
Using Pathozyme Omega Diagnostics IgE Elisa kit, serum IgE 
levels were measured.
PRINCIPLE OF THE TEST:
Test sera were applied to specific monoclonal anti IgE antibody 
coated micro titration wells and incubated with Zero buffer. When human 
IgE is present in the test sample, it will combine with the antibody on the 
well. Residual test sample and IgE antibody are washed with the addition 
of Horse radish peroxidase enzyme. IgE molecules get sandwiched 
between the enzyme linked antibodies and solid phase.  When a substrate 
is added, those wells with IgE produce a colour absorbance which is 
measured at 450mm.  The concentration of IgE is directly proportional to 
the intensity of colour.
STATISTICAL ANALYSIS: 
Is done by Kruskal Wallis H test for two groups (equivalent to chi-
square test) The Kruskal–Wallis test is most commonly used when there 
is one nominal variable and one measurement variable, and the 
measurement variable does not meet the normality assumption of an 
ANOVA (analysis of variance). If the original data set actually consists of 
one nominal variable and one ranked variable, you cannot do an anova 
and must use the Kruskal–Wallis test.
REVIEW
OF
LITERATURE
REVIEW OF LITERATURE
THIRUNAVUKARASU – et - al
           In a cross sectional study done by Thirunavukarasu et al,73 Serum 
IgE levels were estimated in asthmatics and normal subjects between 18 -
60 years of age. They compared the values between various grades of 
asthma and also with control groups. In normal subjects the mean IgE 
level was 151.95 IU/ml and in severe asthmatics it was 1045.32 IU/ ml. 
They reported that serum IgE levels were high in asthmatics as compared 
to normal subjects and also the IgE levels increased as the severity of 
asthma increased.  Though the IgE levels differed significantly with 
severity of asthma it does not completely explain the severity of 
symptoms and signs.  They concluded that there are other factors like 
cytokines which may explain the severity.
ANUPAMA et al
          Anupama et al74 also studied the association of serum IgE levels 
with the magnitude of asthma in adults. Their study group included 132 
patients and 30 healthy controls between 15 – 60 years. The cases were 
categorized in to mild, moderate and severe grades based on history and 
pulmonary function tests. Using chemiluminescence automated system 
the serum IgE levels of the study group was estimated. The average IgE 
levels in control groups, mild, moderate and severe grades of asthma 
were 127.5±2.9 IU/ml, 212.3 ±9.8 IU/ml, 489.2 ±5.4 IU/ml & 1059.6 
±5.9 IU/ml respectively. The values correlated significantly with the 
severity of asthma. They reported that in bronchial asthma the IgE levels 
are elevated substantially and also it reflected the severity.
According to them the extent of inflammation and obstruction of 
airways are related to serum IgE concentrations in asthmatics.
HOGARTH et al
In a Longitudinal epidemiological study of asthmatic and wheezing 
school children in Melbourne by Hogarth et al75 showed that serum IgE 
levels increased in association with increasing frequency and severity of 
asthma. However in this study some controls and mild asthmatics showed 
significant elevation in their serum IgE levels, while some severe 
asthmatics had normal (or) very low levels of IgE.  They came to the 
conclusion that IgE effects its clinical manifestations in cell-associated 
state, rather than as free antibody in the plasma.
SUNYER et al
           Sunyer et al76 analysed the relationship between Total serum IgE 
levels and asthma independent of specific IgE levels to frequent 
environmental allergens. Their sample size consisted of 1,961
symptomatic individuals aged 20 – 24 years. Total and specific serum IgE 
levels to moulds, pets and mites were estimated. They found that patients 
with recent symptoms of asthma showed strong association with Total 
IgE levels.
There was an association between asthma and total IgE even in 
individuals without specific IgE antibodies. They concluded that this 
association could indicate the allergic nature of asthma even in non –
atopic persons.
MEHMET et al
           Mehmet et al77 compared the total serum IgE levels with multiple 
risk factors associated with allergy in children with asthma. In their study, 
140 children (49 female, 91 male) of 3 – 15 years with asthma were 
included. Total IgE was found to be high in males compared to females (p
= 0.03). Serum IgE concentrations correlated well with passive smoking 
(r =0.40, p =0.03), absolute eosinophil count (r =0.46, p = 0.01) and 
number of house hold members (r = 0.41, p =0.02). But they found that 
there was no significant association between breast feeding duration, 
cow’s milk feeding and duration of disease to total IgE levels. They 
finally reported that in children with asthma, the serum IgE levels are 
associated with various factors like sex, crowded family and passive 
smoking.
MELISSA et al 
In a longitudinal study by Melissa et al78 the interaction between 
pediatric asthma and parent and grandparent status was analyzed.  In this 
study children who had a parent with asthma were twice (OR = 1.96)
more likely to have asthma, compared to those children who had a parent 
without asthma.  The chances of asthma was 4 times more in children 
who had parents as well as grandparents with asthma ( OR = 4.27 ).  They 
reported that family history played a significant role as a predictor of 
doctor diagnosed asthma regardless of socio economic status and 
ethnicity.
SHAHID SUKHBIR 
A prospective descriptive study was conducted in wheezing 
children between 0-12 years by Sukhbir79to analyse the impact of passive 
smoking with the age of onset and severity of wheezing.
He found that children who had exposure to house hold tobacco 
smoke had early onset and severe wheeze compared to children who did 
not have exposure to passive smoking.
HARRY HERRICK
Harry  Herrick80 studied the association of duration of breast 
feeding and incidence of asthma in children.  According to this study 
children who were never breastfed or breastfed for less than 3 months 
were found to develop symptoms of asthma at an earlier age.
RESULTS
RESULTS
               
Number of cases in the age groups of 5-8 years and 9-12 years 
were almost same.
               
Maximum numbers of cases were male children.
Table 2                Distribution According to Severity
Severity of Asthma No. of cases Percentage
Intermittent 21 28%
Mild Persistent 16 21%
Moderate persistent 24 32%
Severe persistent 16 19%
Total 75 100%
Majority of asthmatic children belong to moderate persistent 
category.
             
            
            Majority of cases in 5-8 years belong to Intermittent category and 
in 9-12 years maximum number of children where in Moderate persistent 
category.
Table 3          Serum IgE levels in Control groups and Cases
Groups No. of cases Average IgE (IU/ml)
Control 75 89.90
Intermittent 21 206.19
Mild 16 501.25
Moderate 24 815.83
Severe 16 1099.3
IgE levels were elevated in cases compared to controls.  Severe 
asthmatics had high serum IgE levels and low levels were found in 
Intermittent category.
          
The serum IgE levels did not differ significantly in both age groups.
The average IgE levels in both sexes did not vary significantly. 
Table 4          Serum IgE levels based on family History
Family History No. of cases Percentage Average IgE
Parent with 
asthma
27 36% 974
Grandparent 
with asthma
13 17% 612.3
Both Parent and 
Grandparent
with asthma
5 7% 1142
NO family 
history of 
Asthma
30 40% 311
Serum IgE levels were higher in children with both Parents and 
Grandparents having asthma.
           
         
          
         
          Majority of children had history of passive smoking. 
          Children with history of passive smoking had higher IgE levels 
                                               
             
              Majority of children (61%) had history of allergic rhinitis
      
            
                          Among the asthmatic children few cases (16%) had 
history of Allergic Eczema.
           
                     History of allergic conjunctivitis was present in some of the 
children (41%).
            
          
    Children with Atopic eczema had maximum IgE Levels
Table 5                         DURATION OF BREAST FEEDING
Duration of Breast 
feeding
No. Of Cases Percentage
More Than 6 months 31 41.4%
Less Than 6 months 44 58.6%
Total 75 100%
             Majority of Children were Breast fed for less than 6 months
             
          Children who were breastfed for more than 6 months had lower IgE 
levels compared to children who were breastfed for less than 6 months
                                
Table 6                      Duration of the Disease
Duration of Disease No. of Cases Percentage
Less than 4 years 49 65.34%
More than 4 Years 26 34.66%
Total 75 100%
             
               Most of the children had duration of disease less than 4 years
          
                  Longer the duration of disease greater the IgE levels
Table 7   Association between Patient characteristics and Grading of 
Asthma
S.No Variables(N=75) n %
p 
value
Inference
1
Duration of 
disease
<4 
years 31 41
0.00
Significant 
association 
present
>4 
years 44 59
2 Sex
Male 46 61
0.26
No Significant 
association
Female 29 39
3 Family History
1 27 36
0.00
Significant 
association 
present
2 13 17
3 5 7
4 30 40
4
H/o Passive 
smoking
1 42 56
0.00
Significant 
association 
present2 33 44
5
Duration of 
breast feeding
1 31 41
0.00
Significant 
association 
present2 44 59
6
Personal H/O 
Allergic 
conjunctivitis
1 21 28
0.37
No Significant 
association
2 54 72
7
Personal H/O 
Allergic  rhinitis
1 11 15
0.00
Significant 
association 
present2 64 85
8
Personal H/O 
Atopic eczema
1 46 61
0.00
Significant 
association 
present2 29 39
Analysis  done through Epi 
Info 6 Version 3.3.2 Software
Table 8   Association between IgE values and Clinical grading of 
Asthma
Clinical grading n
Mean IgE 
value
Minimum 
IgE value
Maximum 
IgE value
p value*
INTERMITTENT 21 206.1905 70 640
0.00
MILD 16 501.25 465 830
MODERATE 24 815.8333 795 1170
SEVERE 14 1099.2857 1040 1220
*Kruskal-Wallis H test for two groups 
(equivalent to Chi square)
Inference :Mean value of  IgE E is significantly 
associated with clinical grading of asthma
DISCUSSION
DISCUSSION
Asthma is a chronic inflammatory disease of airways with 
increasing number of hospitalizations in young children worldwide. It
poses a significant burden to the patient, family, health care systems and 
government.With advancement in management protocols and health 
education there has been a dramatic reduction in morbidity and mortality.
We studied 75 cases with symptoms and signs suggestive of 
asthma, who were attending the Outpatient as well as admitted in the 
Department of Pediatrics of Government Mohan Kumaramangalam 
Medical College Hospital, Salem from October 2011 to September 2012. 
Our observations are discussed below.
1. AGE DISTRIBUTION:
The proportion of cases in 5-8 years and 9-12 years were 49% and 
51% respectively. In our study the prevalence of cases in both age groups 
were almost equal. According to Anupama et al the proportion of cases 
between 15 -30 years, 31 – 45 years and 46 -60 years were 28%, 47% and 
25% respectively. In their study most of the cases were in 31 – 45 years 
of age.
2. SEX DISTRIBUTION :
Among 75 cases 46 were male children and 29 were female 
children, which corresponds to 61% and 39% respectively.  This shows 
that boys are more affected than girls.  But Anupama et al reported a 
female preponderance in asthmatic adults.
           Male predominance in our study may be due to narrow airways 
and increased tone of airways in children which prompt them to increased 
airflow obstruction in response to various stimuli. Around puberty the 
prevalence becomes higher in female due to alterations in the thoracic 
size that occurs in male but not in female.
3. DISTRIBUTION ACCORDING TO SEVERITY:
Children were categorized into intermittent, mild, moderate and 
severe grades of asthma based on global initiative for asthma guides.  The 
proportions of cases in different categories were 28%, 21%, 32% and 
14% respectively.  The prevalence of children with moderate asthma was 
found to be higher. Anupama et al showed that the proportion of cases 
was more in severe group of asthma.
4. AGE WISE DISTRIBUTION ACCORDING TO SEVERITY 
           In our study between 5-8 years the proportion of cases in 
Intermittent, mild, moderate and severe grades were 35%, 13%, 30% and 
22% respectively.  Majority of children in this age group were found to 
have intermittent asthma.  In 9-12 years the proportions of cases in 
different categories were 21%, 29% 34% and 16% respectively.  Most of 
the children in this age group belonged to moderate category.
Anupama et al reported that majority of cases between 15 – 30 years and 
46 -60 years were in severe group and between 31 - 45 years belonged to 
moderate category.
5. SERUM IGE LEVELS BASED ON SEVERITY 
In our study the mean IgE levels in controls and different grades of 
asthma were 89.90 IU/ml, 206.19 IU/ml, 501.25 IU/ml, 815.83 IU/ml and 
1099.3 IU/ml correspondingly. Serum IgE levels were increased in all 4 
categories of asthma patients when compared to normal control groups.  
As the severity of asthma increased, the serum IgE levels also 
significantly increased.  Patients with severe bronchial asthma had higher 
IgE levels, than intermittent, mild and moderate grades. This finding was 
similar to earlier observations by Thirunavukarasu et al, Anupama et al 
and Hogarth et al.
The principal risk factor in the development of bronchial asthma is 
atopy.  Atopy is production of increased amounts of IgE antibodies 
following exposure to various allergens.
There are several studies which explain the role of serum IgE in the 
development of chronic air flow obstruction.  IgE plays an important role 
in airway obstruction by releasing number of inflammatory mediators like 
histamine, prostaglandins and leukotrienes.
The IgE receptors in atopic individuals send powerful signals 
which result in production of increased levels of Interleukin-4 from mast 
cells.
The elevated Interleukin-4 levels further result in over production 
of IgE antibodies.  The reasons for elevated IgE levels in asthmatics may 
be due to increase in cellular elements of immune system as well as IgE 
dependent processes.  It may also indicate some type of inbuilt propensity 
or presence of disease process relating to airway inflammation.
SERUM IGE LEVELS BASED ON AGE AND SEX
In our study IgE levels was found to be similar in both age groups 
and both sexes. Even though the proportions of cases were high in males, 
the serum IgE levels did not differ significantly in both sexes. Male 
preponderance in our study may be related to the airway anatomy than to 
serum IgE levels.
FAMILIAL PREDISPOSITION
In our study family history of asthma was present in 60% of the 
study population.  36% of children had either one of the parent with 
asthma, 13% of children had one of their grandparents with asthma and 
around 7% of children had one of the parent as well as one of the 
grandparent with asthma. 
There are numerous studies that have revealed that asthma has a 
strong genetic influence.In our study also we have found that there is a 
strong association between parent and grandparent status with the risk of 
development of asthma which is comparable to previous studies.  Also 
the serum IgE levels in this study were higher in children who had 
parents and grandparents with asthma.  This reflects that the severity was 
high in this group.
PASSIVE SMOKING: 
In our study among 75 cases, 40 children had exposure to tobacco 
smoke.  The severity of asthma and serum IgE levels was found to be 
higher in these children compared to those without a history of passive 
smoking.  Passive smoking influences on the severity of asthma by 
increasing the bronchial responsiveness.
Number of studies has shown that children with history of passive 
smoking had greater bronchial responsiveness.  Evans & Collaegues 
reported that the number of emergency room visits for asthma is more in 
children if there is a smoker in the household.  Our study also shows 
similar results that passive smoking has strong relationship to the severity 
of asthma. 
PERSONAL HISTORY OF ATOPY:
In our study the Proportion of cases with history of allergic 
conjunctivitis, rhinitis and eczema were 41%, 61% and 16% respectively.
The severity was more in children with eczema who had elevated 
levels of serum IgE compared to allergic rhinitis and conjunctivitis. But 
Majority of children had history of allergic rhinitis. This was similar to 
the study by Mehmet et al.
There are animal studies that have identified an immune system 
activating protein called Thymic stromal lymphoprotein (TSLP) which 
played an important role in the association between atopic eczema and 
asthma.
It has been estimated that around 50-70% of children with atopic 
eczema subsequently develop asthma.  In our study there is strong 
correlation between eczema and severity of asthma.    
BREAST FEEDING :
In our study, 31(41.4%) cases were breastfed for more than 6 
months and 44(58.6%) were breastfed for less than 6 months. Serum IgE 
levels were low in children who received breast feeding for more than 6 
months.  This reveals the protective role of breast feeding in the 
development of asthma.
Recent studies have also proved that breast feeding the child 
exclusively for 6 months could reduce the incidence of symptoms and 
severity of asthma to some extent.
DURATION OF THE DISEASE:
In our study number of children with duration of asthma < 4 years 
were 49 (65.34%) and duration > 4years were 26 (34.66%). Average IgE
levels in children with duration of asthma less than 4 years was 
520.8IU/ml and in children with duration more than 4 years it was 838.46 
IU/ml. The severity was high in children who had symptoms for more 
than 4 years. According to Mehmet et al the duration of the disease did 
not correlate with the severity of asthma. But our results were comparable 
with the study of Anupama et al. This may be related to the progressive 
decline in lung function as the duration of Disease increases. 
CONCLUSION
                              
CONCLUSION
 Asthma continues to be a chronic disease which is increasing 
in prevalence among children worldwide.  The morbidity 
and mortality due to asthma is still rising.
 Atopy, passive smoking, family history and duration of
breast feeding remain the major risk factors in childhood 
asthma.
 There is strong correlation between atopy and severity of 
asthma.  Especially severity is more in children with atopic 
eczema. Therefore early and effective management of Atopy 
could reduce the severity of asthma.
 Children with persistent exposure to passive smoking and
with positive family history have severe asthma. These 
children should take necessary precautions to avoid the 
triggering factors that may contribute to morbidity.
 Exclusive and prolonged breast feeding plays a vital role in 
decreasing the severity of asthma.Insisting and promoting 
exclusive breast feeding for a period of 6 months and 
continuing it for long periods along with supplementary 
feeds could significantly reduce the severity of asthma in 
children.
 Longer the duration of Asthma, the severity is more.  
Identifying the disease earlier and avoidance of triggering 
factors can reduce the frequent exacerbations.
 IgE has found to play a predominant role both in the 
prevalence and severity of asthma.  Estimation of serum IgE 
levels and assessment of severity helps in effective 
management of asthmatic children.
 Based, on this study, Anti-IgE therapy will be beneficial as 
disease modifying agent in moderate to severe asthmatics. 
But further studies are needed to prove its effectiveness in 
children. 
 There are numerous studies in Adults concerning asthma and 
serum IgE levels, but there are only very few studies in 
children.  Our study will be valuable in the management of 
children with asthma and in reducing the morbidity and 
mortality.
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PROFORMA
       
PROFORMA
Name:                                                                Age:           Sex:    
Contact address:    
                                           
Present complaints:
   Breathing difficulty                                                   yes/no
    Cough                                                                        yes/no
History :
1.    Age of onset of symptoms__________
2.    Frequency of symptoms     < 2 days/ wk    > 2days/ wk                 
daily   continuous
3. Nocturnal symptoms                                               yes/no
           If yes
           No. of episodes in a month  ______________
4.  Interference with physical activity / sleep              yes/no 
5. No. of exacerbations in a month ___________________
6. Febrile/ a febrile episode
7. Trigger induced attack                                             yes/no
           If yes                                   Indoor/ Outdoor
  8. Relief of wheeze with bronchodilators                   yes/no
  9.Seasonal variation                                                    yes/no
  10.Personal h/o   Atopy                                               yes/no
           If yes                                  
            Eczema/ allergic conjunctivits/ allergic rhinitis/others
11. Family h/o asthma                                                 yes/ no
           If yes    parent/Grandparent/Both
  12.   Duration of Breast Feeding   <6 months /> 6months
  13.  H/O Worm Infestation                                        yes/No
General examination:
   Ht:                           Wt:
  Awake                                                                         yes/no                     
  Alert                                                                            yes/no     
  Febrile/afebrile 
  Cyanosis                                                                       yes/no 
Investigations  :
   1) SpO2______%
    2)Serum IgE______ IU/ml(Normal  Male 0-230 IU/ml Female  0-
170 IU/ml )
    3)Peak Flow Metry:               
